ClinicalTrials.gg
TerminatedNCT04816526Updated Oct 8, 2024Results posted

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

A Phase 2 interventional study of Descartes 08 in Myeloma Multiple, sponsored by Cartesian Therapeutics. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Cartesian Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,496th of 1,901
13 · median 36
Started
2021
with 94 others
Phase 2
751 of 2,168
74 open now
Registered
1,718th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,496th largest by enrollment of the 1,901 interventional ones that give a count, is one of 95 that started in 2021, is one of 751 in phase 2, and was the 1,718th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

03

Conditions studied

  • Myeloma Multiple

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be 18 years of age or older at the time of enrollment
  • High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).

Exclusion criteria

Exclusion Criteria:

  • Patients who are pregnant or lactating.
  • Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Descartes 08

    Biological: Descartes 08

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of Stringent Complete Response

    Per IMWG 2016 Response Criteria Summary sCR: Complete response (CR) plus a normal free light chain ratio and no clonal cells in bone marrow (by immunohistochemistry). The FLC ratio must be Kappa/Lambda ≤ 4:1 or ≥ 1:2 after counting at least 100 plasma cells. CR: Negative immunofixation in serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum M-protein detectable by immunofixation (not on electrophoresis) or a ≥ 90% reduction in M-protein, with urine M-protein \<100 mg/24 hours. PR: ≥ 50% reduction in serum M-protein and a ≥ 90% reduction in 24-hour urinary M-protein (or to \<200 mg/24 hours). If M-protein is unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required. If both M-protein and serum-free light chains are unmeasurable, a ≥ 50% reduction in plasma cells is necessary, provided baseline plasma-cell percentage in bone marrow was ≥ 30%. Overall Response (OR): CR+VGPR+PR

    Time frame: 8 months

07

Results

Posted Oct 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneDescartes 08
Started13
Completed13
Not completed0

Outcome measures

PrimaryRate of Stringent Complete Response

Per IMWG 2016 Response Criteria Summary sCR: Complete response (CR) plus a normal free light chain ratio and no clonal cells in bone marrow (by immunohistochemistry). The FLC ratio must be Kappa/Lambda ≤ 4:1 or ≥ 1:2 after counting at least 100 plasma cells. CR: Negative immunofixation in serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum M-protein detectable by immunofixation (not on electrophoresis) or a ≥ 90% reduction in M-protein, with urine M-protein \<100 mg/24 hours. PR: ≥ 50% reduction in serum M-protein and a ≥ 90% reduction in 24-hour urinary M-protein (or to \<200 mg/24 hours). If M-protein is unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required. If both M-protein and serum-free light chains are unmeasurable, a ≥ 50% reduction in plasma cells is necessary, provided baseline plasma-cell percentage in bone marrow was ≥ 30%. Overall Response (OR): CR+VGPR+PR

Time frame:
8 months
Reported as:
Count of participants · Participants
Rate of Stringent Complete Response
ParticipantsDescartes 08
Rate of Stringent Complete Response7

Adverse events

Collected over Through study completion, median follow up of 5.6 months with a range of 2-11 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Descartes 080/13 (0%)1/13 (7.7%)11/13 (84.6%)
Most frequent serious events
Most frequent serious events
EventDescartes 08
FeverImmune system disorders1/13
Most frequent other events
Most frequent other events
EventDescartes 08
FeverImmune system disorders5/13
ThrombocytopeniaBlood and lymphatic system disorders2/13
NeutropeniaBlood and lymphatic system disorders2/13
ChillsImmune system disorders1/13
AnemiaBlood and lymphatic system disorders1/13
DehydrationRenal and urinary disorders1/13
HeadacheNervous system disorders1/13
NauseaGastrointestinal disorders1/13
MyalgiaMusculoskeletal and connective tissue disorders1/13
dizzinessEar and labyrinth disorders1/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Descartes 08
<=18 years0
Between 18 and 65 years8
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Descartes 08
Female8
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Descartes 08
Hispanic or Latino0
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Descartes 08
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Descartes 08
United States10
Turkey3
08

Study locations

2 sites
  • University of California Irvine
    Orange, California 92868, United States
  • Sarah Cannon Research Institute at Tennessee Oncology
    Nashville, Tennessee 37203, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2022, 8 months.

Results were first posted in Oct 2024, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 25, 2021
StartActual
Dec 1, 2021
Primary completionActual
Aug 4, 2022
CompletionActual
Nov 3, 2022
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04816526
Lead sponsor
Cartesian Therapeutics
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Dec 1, 2021
Primary completion
Aug 4, 2022
Completion
Nov 3, 2022
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes

Start the discussion